334 results on '"Lie, W.-R."'
Search Results
2. Preparation and characterization of murine monoclonal antibodies to swine lymphocyte antigens.
- Author
-
Lie, W.-R., Rothschild, M. F., and Warner, C. M.
- Subjects
MONOCLONAL antibodies ,HYBRIDOMAS ,T cells ,ANTIGENS ,LEUCOCYTES ,ENZYME-linked immunosorbent assay - Abstract
A panel of monoclonal antibodies (mAb) was developed by the fusion of Sp2/0 myeloma cells and spleen cells from mice immunized with peripheral blood mononuclear cells (PMNC) or T cells from NIH swine leucocyte antigen (SLA) inbred miniature swine. Twenty stable hybridoma clones were isolated that secreted mAb that reacted with swine PMNC, as determined by an enzyme-linked immunosorbent assay (ELISA). The binding profile to swine PMNC and the ability to fix complement of these mAb were investigated by flow cytometric analyses. The molecular weights of the antigens recognized by six of the mAb were determined by immunoprecipitation of
125 I-surface-labelled PMNC, followed by SDS-PAGE under reducing conditions. The most interesting mAb, 7-34-1 (IgG2a), precipitated a putative MUC class I molecule composed of a 50,000 MW heavy chain and a 12,000 MW light chain (β2 m). This is the third SLA class I-reactive monoclonal antibody to be described for swine. Properties of the mAb described in this paper, mAb 7-34-1, are different from the two other SLA class I-specific mAb that have been described elsewhere in the literature (mAb 74-11-10 and mAb FF85). M onoclonal antibody 7-34-1 recognized class I antigens of SLA haplotypes a, c and din an equivalent manner. This mAb should be especially useful as a general anti- SLA class I reagent for experiments on NIH miniature swine. [ABSTRACT FROM AUTHOR]- Published
- 1988
3. Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous beta 2-microglobulin.
- Author
-
Smith, J D, primary, Lie, W R, additional, Gorka, J, additional, Myers, N B, additional, and Hansen, T H, additional
- Published
- 1992
- Full Text
- View/download PDF
4. Disparate interaction of peptide ligand with nascent versus mature class I major histocompatibility complex molecules: comparisons of peptide binding to alternative forms of Ld in cell lysates and the cell surface.
- Author
-
Smith, J D, primary, Lie, W R, additional, Gorka, J, additional, Kindle, C S, additional, Myers, N B, additional, and Hansen, T H, additional
- Published
- 1992
- Full Text
- View/download PDF
5. The specific binding of peptide ligand to Ld class I major histocompatibility complex molecules determines their antigenic structure.
- Author
-
Lie, W R, primary, Myers, N B, additional, Connolly, J M, additional, Gorka, J, additional, Lee, D R, additional, and Hansen, T H, additional
- Published
- 1991
- Full Text
- View/download PDF
6. Molecular evidence that the H-2D and H-2L genes arose by duplication. Differences between the evolution of the class I genes in mice and humans.
- Author
-
Rubocki, R J, primary, Lee, D R, additional, Lie, W R, additional, Myers, N B, additional, and Hansen, T H, additional
- Published
- 1990
- Full Text
- View/download PDF
7. State of the Art Modelling of the Breast Cancer Metastatic Microenvironment: Where Are We?
- Author
-
Nuckhir, Mia, Withey, David, Cabral, Sara, Harrison, Hannah, and Clarke, Robert B.
- Subjects
METASTATIC breast cancer ,TUMOR microenvironment ,BREAST cancer ,ORGANS (Anatomy) ,DISEASE progression - Abstract
Metastatic spread of tumour cells to tissues and organs around the body is the most frequent cause of death from breast cancer. This has been modelled mainly using mouse models such as syngeneic mammary cancer or human in mouse xenograft models. These have limitations for modelling human disease progression and cannot easily be used for investigation of drug resistance and novel therapy screening. To complement these approaches, advances are being made in ex vivo and 3D in vitro models, which are becoming progressively better at reliably replicating the tumour microenvironment and will in the future facilitate drug development and screening. These approaches include microfluidics, organ-on-a-chip and use of advanced biomaterials. The relevant tissues to be modelled include those that are frequent and clinically important sites of metastasis such as bone, lung, brain, liver for invasive ductal carcinomas and a distinct set of common metastatic sites for lobular breast cancer. These sites all have challenges to model due to their unique cellular compositions, structure and complexity. The models, particularly in vivo, provide key information on the intricate interactions between cancer cells and the native tissue, and will guide us in producing specific therapies that are helpful in different context of metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens.
- Author
-
Hao, Qing, Long, Yuhang, Yang, Yi, Deng, Yiqi, Ding, Zhenyu, Yang, Li, Shu, Yang, and Xu, Heng
- Subjects
CANCER vaccines ,TUMOR antigens ,VACCINE effectiveness ,CLINICAL medicine ,PEPTIDES - Abstract
Neoantigens, presented as peptides on the surfaces of cancer cells, have recently been proposed as optimal targets for immunotherapy in clinical practice. The promising outcomes of neoantigen-based cancer vaccines have inspired enthusiasm for their broader clinical applications. However, the individualized tumor-specific antigens (TSA) entail considerable costs and time due to the variable immunogenicity and response rates of these neoantigens-based vaccines, influenced by factors such as neoantigen response, vaccine types, and combination therapy. Given the crucial role of neoantigen efficacy, a number of bioinformatics algorithms and pipelines have been developed to improve the accuracy rate of prediction through considering a series of factors involving in HLA-peptide-TCR complex formation, including peptide presentation, HLA-peptide affinity, and TCR recognition. On the other hand, shared neoantigens, originating from driver mutations at hot mutation spots (e.g., KRAS
G12D ), offer a promising and ideal target for the development of therapeutic cancer vaccines. A series of clinical practices have established the efficacy of these vaccines in patients with distinct HLA haplotypes. Moreover, increasing evidence demonstrated that a combination of tumor associated antigens (TAAs) and neoantigens can also improve the prognosis, thus expand the repertoire of shared neoantigens for cancer vaccines. In this review, we provide an overview of the complex process involved in identifying personalized neoantigens, their clinical applications, advances in vaccine technology, and explore the therapeutic potential of shared neoantigen strategies. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. Breed and Swine Lymphocyte Antigen Haplotype Differences in Agglutination Titers Following Vaccination with B. Bronchiseptica2
- Author
-
Rothschild, M. F., Chen, H. L., Christian, L. L., Lie, W. R., Venier, L., Cooper, M., Briggs, C., and Warner, C. M.
- Abstract
Genetic differences in immune response to B. bronchiseptica after vaccination with a commercial B. bronchiseptica bacterin were investigated in 1,069 8-wk-old pigs. These pigs were from 65 litters born in the spring and 66 litters born in the fall of 1982 and were purebreds from the Chester White (n = 128), Duroc (n = 281), Hampshire (n = 143), Landrace (n = 309) and Yorkshire (n = 208) breeds. Each litter was raised separately. Individual pigs were vaccinated im at 4 and 6 wk of age with 2 ml of B. bronchiseptica bacterin. At 8 wk of age, 8 ml of blood were collected from each animal and serum prepared to determine agglutinating antibody titers against B. bronchiseptica bacterin by a bacterial agglutination method. In addition, lymphocytes were separated from 1 ml of heparinized blood and used to determine Swine Lymphocyte Antigen (SLA) haplotypes by using cytotoxic antibodies against the SLA complex. Antisera for 3 SLA haplotypes were made available by the National Institutes of Health. Results indicated that breed of pig (P<.01) and dam of pig (P<.01) affected the immune response of the pig after B. bronchiseptica vaccination. Higher immune response was also associated (P<.05) with one of the SLA haplotypes tested. Heritability estimates for immune response following vaccination were .10 ± .12 (half-sib) and .42 ± .19 (full-sib). Results suggest that the relationship of the SLA complex to immune response in the pig and nonadditive genetic and maternal effects on immune response should be further investigated.
- Published
- 1984
- Full Text
- View/download PDF
10. The murine MHC class I genes, H-2Dq and H-2Lq, are strikingly homologous to each other, H-2Ld, and two genes reported to encode tumor-specific antigens.
- Author
-
Lee, D R, Rubocki, R J, Lie, W R, and Hansen, T H
- Abstract
Two phenomena appear to distinguish the D region class I genes from those in the K region in the murine MHC: (a) haplotype disparity in the number of expressed D region class I molecules has been observed; and (b) clines of closely related D region class I molecules among and within mice of different H-2 haplotypes can be defined. Both of these observations have been based on serological and peptide mapping analyses of these molecules. Recent reports using molecular biological approaches have corroborated these findings. Since the mouse strain B10.AKM expresses multiple D region class I antigens, all of which are closely related to the prototypic Ld molecule, we investigated the Dq region of B10.AKM using molecular approaches. Three D region class I genes were isolated from genomic B10.AKM bacteriophage and cosmid libraries. Based on alignment of those genes with the BALB/c D region class I genes by analogous restriction endonuclease sites and by hybridization of one of those genes with a D4d gene-derived oligonucleotide probe, we have designated these genes as Dq, Lq, and D4q. As determined by DNA-mediated gene transfer to mouse L cells followed by serological analyses, the Dq and Lq genes encode previously characterized Dq region class I antigens. The nucleic acid sequence comparisons of the Dq and Lq genes demonstrated a higher level of homology with the Ld and Db genes than with other D region class I genes. In addition, CTL stimulated with a Dq, Lq, or Ld gene transfectant showed strong crossreactions with the other transfectants as targets, suggesting that the products of these genes are also functionally related. Thus, these studies suggest that the L molecule represents a prototypic structure shared by several D region gene products, and furthermore, the duplication of an Ld-like progenitor gene resulted in two Dq region class I genes, Dq and Lq. Unexpectedly, the sequences determined for the Dq and Lq genes are nearly identical to the sequences of two genes, A166 and A149, respectively, which were reported to encode the tumor-specific antigens; these novel class I genes were isolated from an H-2k fibrosarcoma, 1591. This raises the distinct possibility that these purported tumor-specific class I genes were introduced into this tumor by contamination.
- Published
- 1988
- Full Text
- View/download PDF
11. Mapping of C2, Bf, and C4 genes to the swine major histocompatibility complex (swine leukocyte antigen).
- Author
-
Lie, W R, primary, Rothschild, M F, additional, and Warner, C M, additional
- Published
- 1987
- Full Text
- View/download PDF
12. The conformation of Ld induced by beta 2-microglobulin is fixed during de novo synthesis and irreversible by exchange or dissociation.
- Author
-
Myers, N B, primary, Lie, W R, additional, Nett, M, additional, Rubocki, R J, additional, and Hansen, T H, additional
- Published
- 1989
- Full Text
- View/download PDF
13. Zingiber Officinale Roscoe: The Antiarthritic Potential of a Popular Spice—Preclinical and Clinical Evidence.
- Author
-
Szymczak, Joanna, Grygiel-Górniak, Bogna, and Cielecka-Piontek, Judyta
- Abstract
The health benefits of ginger rhizomes (Zingiber officinale Roscoe) have been known for centuries. Recently, ginger root has gained more attention due to its anti-inflammatory and analgesic activities. Many of the bioactive components of ginger may have therapeutic benefits in treating inflammatory arthritis. Their properties seem especially helpful in treating diseases linked to persistent inflammation and pain, symptoms present in the course of the most prevalent rheumatic diseases, such as osteoarthritis (OA) and rheumatoid arthritis (RA). This review analyzes the current knowledge regarding ginger's beneficial anti-inflammatory effect in both in vitro and in vivo studies as well as clinical trials. The drug delivery systems to improve ginger's bioavailability and medicinal properties are discussed. Understanding ginger's beneficial aspects may initiate further studies on improving its bioavailability and therapeutic efficacy and achieving more a comprehensive application in medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Dendritic Cells in Cancer Immunology and Immunotherapy.
- Author
-
Hato, Laura, Vizcay, Angel, Eguren, Iñaki, Pérez-Gracia, José L., Rodríguez, Javier, Gállego Pérez-Larraya, Jaime, Sarobe, Pablo, Inogés, Susana, Díaz de Cerio, Ascensión López, and Santisteban, Marta
- Subjects
TUMOR treatment ,THERAPEUTIC use of antineoplastic agents ,IMMUNOTHERAPY ,CELL physiology ,CANCER vaccines ,CANCER patients ,IMMUNE system ,TUMOR markers ,IMMUNE checkpoint inhibitors ,CANCER chemotherapy ,TUMORS ,T-cell exhaustion ,DENDRITIC cells ,OVERALL survival - Abstract
Simple Summary: Although immune check point inhibitors have been established as a new paradigm in cancer treatment, they have shown no clinical benefit in immune excluded or dessert tumors. Dendritic cells promote and coordinate the immune system. Dendritic cell vaccination enriches tumor milieu and potentiates patient systemic antitumoral responses. In this work we review the strengths and weaknesses of dendritic cell vaccines in different solid tumors regarding their role to improve their clinical efficacy. To date, dendritic cell vaccines have induced immune responses in patients without a significant impact on outcome. Improvements in vaccine formulations, selection of patients and combinations with other antitumoral therapies are needed to increase patients' survival. Cancer immunotherapy modulates the immune system, overcomes immune escape and stimulates immune defenses against tumors. Dendritic cells (DCs) are professional promoters of immune responses against tumor antigens with the outstanding ability to coordinate the innate and adaptive immune systems. Evidence suggests that there is a decrease in both the number and function of DCs in cancer patients. Therefore, they represent a strong scaffold for therapeutic interventions. DC vaccination (DCV) is safe, and the antitumoral responses induced are well established in solid tumors. Although the addition of checkpoint inhibitors (CPIs) to chemotherapy has provided new options in the treatment of cancer, they have shown no clinical benefit in immune desert tumors or in those tumors with dysfunctional or exhausted T-cells. In this way, DC-based therapy has demonstrated the ability to modify the tumor microenvironment for immune enriched tumors and to potentiate systemic host immune responses as an active approach to treating cancer patients. Application of DCV in cancer seeks to obtain long-term antitumor responses through an improved T-cell priming by enhancing previous or generating de novo immune responses. To date, DCV has induced immune responses in the peripheral blood of patients without a significant clinical impact on outcome. Thus, improvements in vaccines formulations, selection of patients based on biomarkers and combinations with other antitumoral therapies are needed to enhance patient survival. In this work, we review the role of DCV in different solid tumors with their strengths and weaknesses, and we finally mention new trends to improve the efficacy of this immune strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Novel polymer-based hydrogels of recent research in drug delivery for disease treatment related to SARS-CoV-2 virus.
- Author
-
Nguyen Hoc Thang, Nguyen Van Phuc, Tran Thi Tu Nhi, Dang Xuan Cuong, and Do Quang Minh
- Abstract
Polymer-based hydrogels are hydrophilic polymer networks with a remarkable capacity to absorb substantial amounts of water and biological fluids, rendering them highly attractive for drug delivery applications. The COVID-19 pandemic has acted as a catalyst for research and innovation in the realm of polymer-based hydrogels for drug delivery, with a particular emphasis on antiviral therapeutics, vaccines, diagnostics, and precision delivery to the respiratory system. The distinctive attributes of hydrogels, such as their biocompatibility, customizable drug release profiles, and ease of functionalization, establish them as versatile platforms for the development of advanced drug delivery systems to combat not only COVID-19 but also a spectrum of other infectious diseases. This study is dedicated to scrutinizing and evaluating the characteristics of polymer-based hydrogels employed in drug delivery for the treatment of diseases associated with the SARS-CoV-2 virus. Furthermore, the investigation introduces a novel classification system for polymer-based hydrogels deployed in drug delivery for SARS-CoV-2-related diseases. Additionally, the paper provides an up-to-date evaluation of the latest developed hydrogels utilized in drug delivery for the treatment of diseases linked to the SARS-CoV-2 virus, based on research conducted through the recent months of 2023. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. MarketLine Company Profile: W. R. Berkley Corp.
- Published
- 2023
17. Spleen‐targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma.
- Author
-
Wu, Ming, Luo, Zijin, Cai, Zhixiong, Mao, Qianqian, Li, Zhenli, Li, Hao, Zhang, Cao, Zhang, Yuting, Zhong, Aoxue, Wu, Liming, and Liu, Xiaolong
- Abstract
Neoantigens are emerging as attractive targets to develop personalized cancer vaccines, but their immunization efficacy is severely hampered by their restricted accessibility to lymphoid tissues where immune responses are initiated. Leveraging the capability of red blood cells (RBCs) to capture and present pathogens in peripheral blood to the antigen‐presenting cells (APCs) in spleen, we developed a RBC‐driven spleen targeting strategy to deliver DNA vaccine encoding hepatocellular carcinoma (HCC) neoantigen. The DNA vaccine‐encapsulating polymeric nanoparticles that were intentionally hitchhiked on the preisolated RBCs could preferentially accumulate in the spleen to promote the neoantigen expression by APCs, resulting in the burst of neoantigen‐specific T‐cell immunity to prevent tumorigenesis in a personalized manner, and slow down tumor growth in the established aggressively growing HCC. Remarkably, when combined with anti‐PD‐1, the vaccine achieved complete tumor regression and generated a robust systemic immune response with long‐term tumor‐specific immunological memory, which thoroughly prevented tumor recurrence and spontaneous lung metastasis. This study offers a prospective strategy to develop personalized neoantigen vaccines for augmenting cancer immunotherapy efficiency in immune "cold" HCC. Synopsis: To address the limited efficacy of current personalized cancer vaccines and improve hepatocellular carcinoma (HCC) immunotherapy, a red blood cell (RBC) hitchhiking strategy was developed for targeted delivery of a neoantigen DNA vaccine to the spleen.Polymer‐lipid nanoparticles (NPs) were designed to encapsulate neoantigen‐carrying plasmid DNA (pDNA). These nanovaccines were then attached to pre‐isolated RBCs to spread DNA vaccine delivery.RBC‐hitchhiking DNA nanovaccines preferentially accumulated in the spleen, promoting neoantigen expression by antigen‐presenting cells (APCs) and inducing a strong neoantigen‐specific T cell response.This vaccination regimen prevented tumorigenesis in a personalized manner and slowed down tumor growth in the aggressively growing HCC tumor characterized by an immune "cold" microenvironment.Combining RBC‐hitchhiking DNA nanovaccines with anti‐PD‐1 checkpoint blockade led to complete tumor regression (75 and 100% in subcutaneous and orthotopic HCC mouse models, respectively) and prolonged mouse survival. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Lupus Nephritis Risk Factors and Biomarkers: An Update.
- Author
-
Renaudineau, Yves, Brooks, Wesley, and Belliere, Julie
- Subjects
LUPUS nephritis ,ANTINUCLEAR factors ,DRUG monitoring ,SYSTEMIC lupus erythematosus ,BIOMARKERS ,EARLY death - Abstract
Lupus nephritis (LN) represents the most severe organ manifestation of systemic lupus erythematosus (SLE) in terms of morbidity and mortality. To reduce these risks, tremendous efforts have been made in the last decade to characterize the different steps of the disease and to develop biomarkers in order to better (i) unravel the pre-SLE stage (e.g., anti-nuclear antibodies and interferon signature); (ii) more timely initiation of therapy by improving early and accurate LN diagnosis (e.g., pathologic classification was revised); (iii) monitor disease activity and therapeutic response (e.g., recommendation to re-biopsy, new urinary biomarkers); (iv) prevent disease flares (e.g., serologic and urinary biomarkers); (v) mitigate the deterioration in the renal function; and (vi) reduce side effects with new therapeutic guidelines and novel therapies. However, progress is poor in terms of improvement with early death attributed to active SLE or infections, while later deaths are related to the chronicity of the disease and the use of toxic therapies. Consequently, an individualized treat-to-target strategy is mandatory, and for that, there is an unmet need to develop a set of accurate biomarkers to be used as the standard of care and adapted to each stage of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.
- Author
-
Abascal, Jensen, Oh, Michael S., Liclican, Elvira L., Dubinett, Steven M., Salehi-Rad, Ramin, and Liu, Bin
- Subjects
NON-small-cell lung carcinoma ,DENDRITIC cells ,TUMOR microenvironment ,TUMOR antigens ,ANTIGEN presentation ,CELL communication - Abstract
Non-small-cell lung cancer (NSCLC) remains one of the leading causes of death worldwide. While NSCLCs possess antigens that can potentially elicit T cell responses, defective tumor antigen presentation and T cell activation hinder host anti-tumor immune responses. The NSCLC tumor microenvironment (TME) is composed of cellular and soluble mediators that can promote or combat tumor growth. The composition of the TME plays a critical role in promoting tumorigenesis and dictating anti-tumor immune responses to immunotherapy. Dendritic cells (DCs) are critical immune cells that activate anti-tumor T cell responses and sustain effector responses. DC vaccination is a promising cellular immunotherapy that has the potential to facilitate anti-tumor immune responses and transform the composition of the NSCLC TME via tumor antigen presentation and cell–cell communication. Here, we will review the features of the NSCLC TME with an emphasis on the immune cell phenotypes that directly interact with DCs. Additionally, we will summarize the major preclinical and clinical approaches for DC vaccine generation and examine how effective DC vaccination can transform the NSCLC TME toward a state of sustained anti-tumor immune signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations.
- Author
-
Lee, Kyu-Won, Yam, Judy Wai Ping, and Mao, Xiaowen
- Subjects
DENDRITIC cells ,CANCER vaccines ,VACCINES ,BIOMATERIALS ,IMMUNE checkpoint proteins ,EXTRACELLULAR vesicles ,PROGRAMMED cell death 1 receptors - Abstract
In the emerging era of cancer immunotherapy, immune checkpoint blockades (ICBs) and adoptive cell transfer therapies (ACTs) have gained significant attention. However, their therapeutic efficacies are limited due to the presence of cold type tumors, immunosuppressive tumor microenvironment, and immune-related side effects. On the other hand, dendritic cell (DC)-based vaccines have been suggested as a new cancer immunotherapy regimen that can address the limitations encountered by ICBs and ACTs. Despite the success of the first generation of DC-based vaccines, represented by the first FDA-approved DC-based therapeutic cancer vaccine Provenge, several challenges remain unsolved. Therefore, new DC vaccine strategies have been actively investigated. This review addresses the limitations of the currently most adopted classical DC vaccine and evaluates new generations of DC vaccines in detail, including biomaterial-based, immunogenic cell death-inducing, mRNA-pulsed, DC small extracellular vesicle (sEV)-based, and tumor sEV-based DC vaccines. These innovative DC vaccines are envisioned to provide a significant breakthrough in cancer immunotherapy landscape and are expected to be supported by further preclinical and clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Usefulness of Docking and Molecular Dynamics in Selecting Tumor Neoantigens to Design Personalized Cancer Vaccines: A Proof of Concept.
- Author
-
Amaya-Ramirez, Diego, Martinez-Enriquez, Laura Camila, and Parra-López, Carlos
- Subjects
CANCER vaccines ,MOLECULAR dynamics ,MOLECULAR docking ,PROOF of concept ,BACTERIAL vaccines ,PEPTIDES - Abstract
Personalized cancer vaccines based on neoantigens are a new and promising treatment for cancer; however, there are still multiple unresolved challenges to using this type of immunotherapy. Among these, the effective identification of immunogenic neoantigens stands out, since the in silico tools used generate a significant portion of false positives. Inclusion of molecular simulation techniques can refine the results these tools produce. In this work, we explored docking and molecular dynamics to study the association between the stability of peptide–HLA complexes and their immunogenicity, using as a proof of concept two HLA-A2-restricted neoantigens that were already evaluated in vitro. The results obtained were in accordance with the in vitro immunogenicity, since the immunogenic neoantigen ASTN1 remained bound at both ends to the HLA-A2 molecule. Additionally, molecular dynamic simulation suggests that position 1 of the peptide has a more relevant role in stabilizing the N-terminus than previously proposed. Likewise, the mutations may have a "delocalized" effect on the peptide–HLA interaction, which means that the mutated amino acid influences the intensity of the interactions of distant amino acids of the peptide with the HLA. These findings allow us to propose the inclusion of molecular simulation techniques to improve the identification of neoantigens for cancer vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Functionalized nanoparticles crossing the brain-blood barrier to target glioma cells.
- Author
-
Yongyan Wu, Yufeng Qian, Wei Peng, and Xuchen Qi
- Subjects
CENTRAL nervous system tumors ,BLOOD-brain barrier ,GLIOMAS ,DRUG delivery systems ,IMMUNE checkpoint inhibitors ,DRUG therapy - Abstract
Glioma is the most common tumor of the central nervous system (CNS), with a 5-year survival rate of <35%. Drug therapy, such as chemotherapeutic and immunotherapeutic agents, remains one of the main treatment modalities for glioma, including temozolomide, doxorubicin, bortezomib, cabazitaxel, dihydroartemisinin, immune checkpoint inhibitors, as well as other approaches such as siRNA, ferroptosis induction, etc. However, the filter function of the blood-brain barrier (BBB) reduces the amount of drugs needed to effectively target CNS tumors, making it one of the main reasons for poor drug efficacies in glioma. Thus, finding a suitable drug delivery platform that can cross the BBB, increase drug aggregation and retainment in tumoral areas and avoid accumulation in non-targeted areas remains an unsolved challenge in glioma drug therapy. An ideal drug delivery system for glioma therapy should have the following features: (1) prolonged drug life in circulation and effective penetration through the BBB; (2) adequate accumulation within the tumor (3) controlled-drug release modulation; (4) good clearance from the body without significant toxicity and immunogenicity, etc. In this regard, due to their unique structural features, nanocarriers can effectively span the BBB and target glioma cells through surface functionalization, providing a new and effective strategy for drug delivery. In this article, we discuss the characteristics and pathways of different nanocarriers for crossing the BBB and targeting glioma by listing different materials for drug delivery platforms, including lipid materials, polymers, nanocrystals, inorganic nanomaterials, etc. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Polymer-Based Hydrogels Applied in Drug Delivery: An Overview.
- Author
-
Thang, Nguyen Hoc, Chien, Truong Bach, and Cuong, Dang Xuan
- Subjects
HYDROGELS in medicine ,BIOLOGICAL fluid dynamics ,BIOCOMPATIBILITY ,MEDICAL care costs ,BIOPOLYMERS - Abstract
Polymer-based hydrogels are hydrophilic polymer networks with crosslinks widely applied for drug delivery applications because of their ability to hold large amounts of water and biological fluids and control drug release based on their unique physicochemical properties and biocompatibility. Current trends in the development of hydrogel drug delivery systems involve the release of drugs in response to specific triggers such as pH, temperature, or enzymes for targeted drug delivery and to reduce the potential for systemic toxicity. In addition, developing injectable hydrogel formulations that are easily used and sustain drug release during this extended time is a growing interest. Another emerging trend in hydrogel drug delivery is the synthesis of nano hydrogels and other functional substances for improving targeted drug loading and release efficacy. Following these development trends, advanced hydrogels possessing mechanically improved properties, controlled release rates, and biocompatibility is developing as a focus of the field. More complex drug delivery systems such as multi-drug delivery and combination therapies will be developed based on these advancements. In addition, polymer-based hydrogels are gaining increasing attention in personalized medicine because of their ability to be tailored to a specific patient, for example, drug release rates, drug combinations, target-specific drug delivery, improvement of disease treatment effectiveness, and healthcare cost reduction. Overall, hydrogel application is advancing rapidly, towards more efficient and effective drug delivery systems in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Function and Regulation of Bone Marrow Adipose Tissue in Health and Disease: State of the Field and Clinical Considerations.
- Author
-
Zhang X, Tian L, Majumdar A, and Scheller EL
- Subjects
- Humans, Animals, Adipocytes metabolism, Adipocytes physiology, Adipogenesis physiology, Bone Marrow metabolism, Bone Marrow physiology, Adipose Tissue metabolism, Adipose Tissue physiology
- Abstract
Bone marrow adipose tissue (BMAT) is a metabolically and clinically relevant fat depot that exists within bone. Two subtypes of BMAT, regulated and constitutive, reside in hematopoietic-rich red marrow and fatty yellow marrow, respectively, and exhibit distinct characteristics compared to peripheral fat such as white and brown adipose tissues. Bone marrow adipocytes (BMAds) are evolutionally preserved in most vertebrates, start development after birth and expand throughout life, and originate from unique progenitor populations that control bone formation and hematopoiesis. Mature BMAds also interact closely with other cellular components of the bone marrow niche, serving as a nearby energy reservoir to support the skeletal system, a signaling hub that contributes to both local and systemic homeostasis, and a final fuel reserve for survival during starvation. Though BMAT and bone are often inversely correlated, more BMAT does not always mean less bone, and the prevention of BMAT expansion as a strategy to prevent bone loss remains questionable. BMAT adipogenesis and lipid metabolism are regulated by the nervous systems and a variety of circulating hormones. This contributes to the plasticity of BMAT, including BMAT expansion in common physiological or pathological conditions, and BMAT catabolism under certain extreme circumstances, which are often associated with malnutrition and/or systemic inflammation. Altogether, this article provides a comprehensive overview of the local and systemic functions of BMAT and discusses the regulation and plasticity of this unique adipose tissue depot in health and disease. © 2024 American Physiological Society. Compr Physiol 14:5521-5579, 2024., (Copyright © 2024 American Physiological Society. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. MarketLine Company Profile: W. R. Berkley Corp.
- Published
- 2022
26. Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy.
- Author
-
Biri-Kovács, Beáta, Bánóczi, Zoltán, Tummalapally, Anitha, and Szabó, Ildikó
- Subjects
PEPTIDES ,TUMOR antigens ,SKIN cancer ,MELANOMA ,VACCINE development - Abstract
Cancer of the skin is by far the most common of all cancers. Although the incidence of melanoma is relatively low among skin cancers, it can account for a high number of skin cancer deaths. Since the start of deeper insight into the mechanisms of melanoma tumorigenesis and their strong interaction with the immune system, the development of new therapeutical strategies has been continuously rising. The high number of melanoma cell mutations provides a diverse set of antigens that the immune system can recognize and use to distinguish tumor cells from normal cells. Peptide-based synthetic anti-tumor vaccines are based on tumor antigens that elicit an immune response due to antigen-presenting cells (APCs). Although targeting APCs with peptide antigens is the most important assumption for vaccine development, peptide antigens alone are poorly immunogenic. The immunogenicity of peptide antigens can be improved not only by synthetic modifications but also by the assistance of adjuvants and/or delivery systems. The current review summarizes the different chemical approaches for the development of effective peptide-based vaccines for the immunotherapeutic treatment of advanced melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy.
- Author
-
Liao, Weixin, Huang, Shaozhuo, Li, Lin, Wang, Jialiang, Li, Jing, Chen, Yongjian, Chen, Lubiao, Lian, Yifan, and Huang, Yuehua
- Subjects
THERAPEUTIC use of antineoplastic agents ,GENETIC mutation ,IMMUNE checkpoint inhibitors ,CANCER chemotherapy ,CARCINOGENESIS ,WESTERN immunoblotting ,IMMUNOHISTOCHEMISTRY ,ONCOGENES ,BIOINFORMATICS ,GLYCOSIDASES ,GENE expression profiling ,RESEARCH funding ,TUMORS ,POLYMERASE chain reaction ,CHEMOKINES ,IMMUNOTHERAPY - Abstract
Simple Summary: A reliable efficacy predictor for immunotherapy is warranted due to its unsatisfying responsive rate among cancer patients. Endonuclease VIII-like protein 3 (NEIL3) is a DNA glycosylase reported to be heightened in specific cancers. However, little is known regarding the immunological features of NEIL3 among cancers. Here, a pan-cancer landscape was presented to elucidate the characteristics of NEIL3 in the tumor microenvironment (TME). In this study, we demonstrated that NEIL3 may be a promising indicator for tumor prognosis, immunotherapy, and chemotherapy. With the aim of enhancing the understanding of NEIL3 in prognosis prediction and therapy administration, we conducted a pan-cancer landscape analysis on NEIL3. The mutation characteristics, survival patterns, and immune features of NEIL3 across cancers were analyzed. Western blotting, qPCR, and immunohistochemistry were conducted to validate the bioinformatics results. The correlation between NEIL3 and chemotherapeutic drugs, as well as immunotherapies, was estimated. NEIL3 was identified as an oncogene with prognostic value in predicting clinical outcomes in multiple cancers. Combined with the neoantigen, tumor mutational burden (TMB), and microsatellite instability (MSI) results, a strong relationship between NEIL3 and the TME was observed. NEIL3 was demonstrated to be closely associated with multiple immune parameters, including infiltrating immunocytes and pro-inflammatory chemokines, which was verified by experiments. More importantly, patients with a higher expression of NEIL3 were revealed to be more sensitive to chemotherapeutic regimens and immune checkpoint inhibitors in selected cancers, implying that NEIL3 may be an indicator for therapeutic administration. Our study indicated NEIL3 has a strong association with the immune microenvironment and phenotypic changes in certain types of cancers, which facilitated the improved understanding of NEIL3 across cancers and highlighted the potential for clinical application of NEIL3 in precision medical stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Oral Supplementation with Three Vegetable Oils Differing in Fatty Acid Composition Alleviates High-Fat Diet-Induced Obesity in Mice by Regulating Inflammation and Lipid Metabolism.
- Author
-
Aldamarany, Waleed A. S., Huang Taocui, Deng Liling, Yang Wanfu, and Geng Zhong
- Subjects
VEGETABLE oils ,DIETARY supplements ,FATTY acid synthases ,LIPID metabolism ,ASPARTATE aminotransferase ,LIPIDS ,FATTY acids - Abstract
Obesity has become one of the most prevalent chronic diseases worldwide, which affects people's health and daily lives. Therefore, this study aimed to investigate the anti-obesity effects of perilla seed oil (PSO), sunflower oil (SFO), and tea seed oil (TSO) and their potential mechanisms in mice fed a high-fat diet (HFD). Mice were divided into five groups: ND, mice fed a normal diet; HFD, mice fed a high-fat diet; PSO, SFO, and TSO, mice fed a high-fat diet supplemented with PSO, SFO, and TSO at 2 g/kg body weight per day, respectively. Our findings showed that oral supplementation with all three oils for 8 weeks significantly reduced body weight, tissue weight, insulin resistance index, serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and free fatty acids (FFA), and markedly alleviated hyperglycemia, hyperlipidemia, and hepatic steatosis in obese mice. It also decreased leptin, pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and (IL)-1beta (IL-1β), and increased anti-inflammatory adipokine adiponectin at both secretion and mRNA expression levels in the epididymal adipose tissue (EAT). Moreover, PSO, SFO, and TSO administration increased the expression levels of fatty acid β-oxidation-related genes, including peroxisome proliferator-activated receptor-alpha (PPAR-α), carnitine palmitoyltransferase 1a (CPT1a) and CPT1b, and thermogenesis-related genes such as uncoupling protein 1 (UCP1), and decreased the expression levels of lipid synthesis-related genes, including fatty acid synthase (FAS) and PPAR-γ in EAT. In conclusion, PSO, SFO, and TSO supplementation could have potential anti-obesity effects in HFD-fed mice by reducing inflammation and improving lipid metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Chemoprevention by Microencapsulated Lactiplantibacillus Plantarum LAB12 Against Orthotopic Colorectal Cancer Mice is Associated with Apoptosis and Anti-angiogenesis.
- Author
-
Fareez IM, Lim SM, and Ramasamy K
- Subjects
- Rats, Mice, Female, Animals, Rats, Sprague-Dawley, Capsules, Mice, Nude, Chemoprevention, Apoptosis, Lactobacillus plantarum physiology, Probiotics, Colorectal Neoplasms
- Abstract
The pathogenesis of colorectal cancer (CRC) is associated with gut dysbiosis that is attributed to unhealthy lifestyles and dietary habits. Consumption of microencapsulated probiotics may potentially restore the gut microbiota in favour of prevention against CRC. This study determined the fate of microencapsulated Lactiplantibacillus plantarum (formerly known as Lactobacillus plantarum) LAB12 in the gastrointestinal tract (GIT) and assessed the chemopreventive effect of microencapsulated L. plantarum LAB12 in vivo. The targeted release of L. plantarum LAB12 from Alg-based microcapsules at the stomach, ileum, caecum and colon of Sprague-Dawley rats was examined by confocal microscopy and qPCR. Microcapsules loaded with L. plantarum LAB12 remained intact in the stomach. Free L. plantarum LAB12 were present in abundance (> 7 log CFU) only in the intestines. Subsequently, the chemopreventive properties of microencapsulated L. plantarum LAB12 were validated against NU/NU nude mice bearing orthotopic transplanted CT-26 CRC (12 female mice; 4-6 weeks old; 20-22 g; n = 6/group). Orthotopic mice pre-supplemented with microencapsulated L. plantarum LAB12 (10 log CFU kg
-1 BW for 11 weeks) were presented with significantly (p < 0.05) reduced tumour volume (- 98.87%) and weight (- 89.27%) when compared to control. Western blots indicated that the chemopreventive effect could be attributed to apoptosis and anti-angiogenesis mediated, at least in part, through upregulation of tumour suppressor p53 (+ 45.4%) and pro-apoptotic caspase-3 (+ 82.4%), and downregulation of pro-inflammatory COX-2 (- 57.9%), pro-angiogenic VEGF (- 66.8%) and PECAM-1 (-64.1%). Altogether, this study strongly implied the possibility of having L. plantarum LAB12-loaded microcapsules safely incorporated into food and nutraceutical products for prevention against CRC., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
30. Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination—A Retrospective Observation.
- Author
-
Zelba, Henning, McQueeney, Alex, Rabsteyn, Armin, Bartsch, Oliver, Kyzirakos, Christina, Kayser, Simone, Harter, Johannes, Latzer, Pauline, Hadaschik, Dirk, Battke, Florian, Hartkopf, Andreas D., and Biskup, Saskia
- Subjects
ADJUVANT treatment of cancer ,PEPTIDES ,CANCER patients ,VACCINATION ,IMMUNOLOGICAL adjuvants ,HISTOCOMPATIBILITY antigens ,BCG vaccines - Abstract
Breast cancer is a tumor entity that is one of the leading causes of mortality among women worldwide. Although numerous treatment options are available, current explorations of personalized vaccines have shown potential as promising new treatment options to prevent the recurrence of cancer. Here we present a small proof of concept study using a prophylactic peptide vaccination approach in four female breast cancer patients who achieved remission after standard treatment. The patients were initially analyzed for somatic tumor mutations and then treated with personalized neoantigen-derived peptide vaccines. These vaccines consisted of HLA class I and class II peptides and were administered intracutaneously followed by subcutaneous application of sargramostim and/or topical imiquimod as an immunological adjuvant. After an initial priming phase of four vaccinations within two weeks, patients received monthly boosting/maintenance vaccinations. Chemotherapy or checkpoint inhibition was not performed during vaccination. One patient received hormone therapy. The vaccines were well tolerated with no serious adverse events. All patients displayed vaccine-induced CD4+ and/or CD8+ T-cell responses against various neoantigens. Furthermore, all patients remained tumor-free and had persistent T-cell responses, even several months after the last vaccination, suggesting the potential of peptide vaccines as an immunosurveillance and long term prophylaxis option. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Breed and swine lymphocyte antigen haplotype differences in agglutination titers following vaccination with B. bronchiseptica
- Author
-
Cooper, M., Christian, L. L., Briggs, C., Rothschild, M. F., Chen, H. L., Warner, C. M., Lie, W. R., and Venier, L.
- Subjects
GENETICS ,IMMUNE response ,NATURAL immunity - Published
- 1984
32. The role of bone marrow adipocytes in cancer progression: the impact of obesity.
- Author
-
Hernandez, Marine, Shin, Sauyeun, Muller, Catherine, and Attané, Camille
- Abstract
Bone marrow adipose tissues (BMATs) and their main cellular component, bone marrow adipocytes (BMAds), are found within the bone marrow (BM), which is a niche for the development of hematological malignancies as well as bone metastasis from solid tumors such as breast and prostate cancers. In humans, BMAds are present within the hematopoietic or "red" BMAT and in the "yellow" BMAT where they are more densely packed. BMAds are emerging as new actors in tumor progression; however, there are many outstanding questions regarding their precise role. In this review, we summarized our current knowledge regarding the development, distribution, and regulation by external stimuli of the BMATs in mice and humans and addressed how obesity could affect these traits. We then discussed the specific metabolic phenotype of BMAds that appear to be different from "classical" white adipocytes, since they are devoid of lipolytic function. According to this characterization, we presented how tumor cells affect the in vitro and in vivo phenotype of BMAds and the signals emanating from BMAds that are susceptible to modulate tumor behavior with a specific emphasis on their metabolic crosstalk with cancer cells. Finally, we discussed how obesity could affect this crosstalk. Deciphering the role of BMAds in tumor progression would certainly lead to the identification of new targets in oncology in the near future. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Next Steps for Immunotherapy in Glioblastoma.
- Author
-
Cao, Toni Q., Wainwright, Derek A., Lee-Chang, Catalina, Miska, Jason, Sonabend, Adam M., Heimberger, Amy B., and Lukas, Rimas V.
- Subjects
GLIOMA treatment ,LITERATURE reviews ,IMMUNOTHERAPY - Abstract
Simple Summary: Prognosis for glioblastoma patients remains poor despite the current standard of care treatments. More recent investigations have focused on immunotherapy, which utilizes a patient's immune system to target cancer cells. Though proven to be successful in non-central nervous system cancers, immunotherapies have yielded disappointing results for glioblastoma thus far. A variety of factors play into the efficacy of immunotherapy for glioblastoma and have become new areas of interest. Here we review both historical and emerging immunotherapeutic approaches, as well as the molecular factors that have been shown to impact the efficacy of immunotherapies. Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Tumour Derived Extracellular Vesicles: Challenging Target to Blunt Tumour Immune Evasion.
- Author
-
Lopatina, Tatiana, Sarcinella, Alessandro, and Brizzi, Maria Felice
- Subjects
TUMOR prevention ,TUMOR diagnosis ,DISEASE progression ,IMMUNE system ,METASTASIS ,CELL communication ,TUMORS ,TUMOR markers ,EXTRACELLULAR vesicles - Abstract
Simple Summary: Tumour onset and development occur because of specific immune support. The immune system, which is originally able to perceive and eliminate incipient cancer cells, becomes suppressed and hijacked by cancer. For these purposes, tumour cells use extracellular vesicles (TEVs). Specific molecular composition allows TEVs to reprogram immune cells towards tumour tolerance. Circulating TEVs move from their site of origin to other organs, preparing "a fertile soil" for metastasis formation. This implies that TEV molecular content can provide a valuable tool for cancer biomarker discovery and potential targets to reshape the immune system into tumour recognition and eradication. Control of the immune response is crucial for tumour onset and progression. Tumour cells handle the immune reaction by means of secreted factors and extracellular vesicles (EV). Tumour-derived extracellular vesicles (TEV) play key roles in immune reprogramming by delivering their cargo to different immune cells. Tumour-surrounding tissues also contribute to tumour immune editing and evasion, tumour progression, and drug resistance via locally released TEV. Moreover, the increase in circulating TEV has suggested their underpinning role in tumour dissemination. This review brings together data referring to TEV-driven immune regulation and antitumour immune suppression. Attention was also dedicated to TEV-mediated drug resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Calreticulin as an Adjuvant to Promote Dendritic Cell Maturation and Enhance Antigen-Specific T Lymphocyte Responses against Melanoma.
- Author
-
Gong, Zheng, Chen, Ming, Miao, Jie, Han, Chao-Jie, Zhong, Qiao, Gong, Fang-Yuan, and Gao, Xiao-Ming
- Subjects
T cells ,CYTOTOXIC T cells ,DENDRITIC cells ,CALRETICULIN ,CHIMERIC proteins ,MELANOMA treatment ,ALBUMINS ,MELANOMA ,ANIMAL experimentation ,IMMUNOMODULATORS ,CANCER vaccines ,CALCIUM-binding proteins ,MICE - Abstract
An endoplasmic reticulum resident protein, calreticulin (CRT), participates in many cellular processes. CRT is a tumor-associated antigen with an important role in antitumor immunity. Previously, we reported that the recombinant CRT fragment 39-272 (CRT/39-272) exhibited superior immunobiological activity, activating macrophages to release cytokines and promoting dendritic cell (DC) maturation. However, the effect of CRT/39-272 in vivo, especially its adjuvant effect on in vivo antitumor immune responses, was not fully investigated. In this study, we constructed a fusion protein linking CRT/39-272 to an ovalbumin (OVA) peptide (residues 182-297, OVAp) and used the fusion protein (OVAp-CRT) to examine the adjuvant effect of CRT. We investigated whether CRT/39-272 could induce bone marrow-derived DC maturation and strongly promote the proliferation of OVA-specific T cells in vitro. Compared with OVAp, OVAp-CRT induced stronger antigen-specific T lymphocyte responses, including antigen-specific T cell proliferation, interferon-γ secretion, and cytotoxic T lymphocyte responses. OVAp-CRT-immunized mice generated significantly increased OVAp-specific antibody and CD4+/CD8+ memory T cells, which mediated long-term protective effects. OVAp-CRT upregulated CD40, CD80, and CD86 expressions in splenic conventional DCs. Furthermore, OVAp-CRT protected immunized mice against OVA-expressing B16 melanoma cells in vivo. Moreover, mice that were adoptively transferred with OVAp-CRT-pulsed DCs showed inhibited tumor growth and prolonged mouse survival. Our results demonstrate that CRT/39-272 can be used as a potential new adjuvant for tumor vaccines, and this finding may be useful in tumor vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
- Author
-
Ichimiya, Shu, Fujimura, Akiko, Masuda, Muneyuki, Masuda, Shogo, Yasumatsu, Ryuji, Umebayashi, Masayo, Tanaka, Hiroto, Koya, Norihiro, Nakagawa, Shinichiro, Yew, Poh Yin, Yoshimura, Sachiko, Onishi, Hideya, Nakamura, Masafumi, Nakamura, Yusuke, and Morisaki, Takashi
- Subjects
T cells ,DENDRITIC cells ,CYTOTOXIC T cells ,MONONUCLEAR leukocytes ,NIVOLUMAB - Abstract
Although immune checkpoint inhibitors (ICIs) have emerged as new therapeutic options for refractory cancer, they are only effective in select patients. Tumor antigen-pulsed dendritic cell (DC) vaccine therapy activates tumor-specific cytotoxic T lymphocytes, making it an important immunotherapeutic strategy. Salivary ductal carcinoma (SDC) carries a poor prognosis, including poor long-term survival after metastasis or recurrence. In this study, we reported a case of refractory metastatic SDC that was treated with a tumor lysate-pulsed DC vaccine followed by a single injection of low-dose nivolumab, and a durable complete response was achieved. We retrospectively analyzed the immunological factors that contributed to these long-lasting clinical effects. First, we performed neoantigen analysis using resected metastatic tumor specimens obtained before treatment. We found that the tumor had 256 non-synonymous mutations and 669 class I high-affinity binding neoantigen peptides. Using synthetic neoantigen peptides and ELISpot analysis, we found that peripheral blood mononuclear leukocytes cryopreserved before treatment contained pre-existing neoantigen-specific T cells, and the cells obtained after treatment exhibited greater reactivity to neoantigens than those obtained before treatment. Our results collectively suggest that the rapid and long-lasting effect of this combination therapy in our patient may have resulted from the presence of pre-existing neoantigen-specific T cells and stimulation and expansion of those cells following tumor lysate-pulsed DC vaccine and ICI therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. MarketLine Company Profile: W. R. Berkley Corp.
- Published
- 2021
38. Leveraging STING, Batf3 Dendritic Cells, CXCR3 Ligands, and Other Components Related to Innate Immunity to Induce A "Hot" Tumor Microenvironment That Is Responsive to Immunotherapy.
- Author
-
Reschke, Robin and Olson, Daniel J.
- Subjects
DENDRITIC cells ,NATURAL immunity ,CELL physiology ,LITERATURE reviews ,IMMUNOTHERAPY - Abstract
Simple Summary: The conceptualization of a "hot" tumor microenvironment has been characterized by mainly T cell infiltration, whereas, "cold" or "immune-deserted" tumors were seen as lacking T cells. However, the presence of antigen-presenting myeloid cells is equally important. In particular, Batf3-lineage DCs are highly efficient in priming effector T cells. Additionally, they can recruit T cells with CXCR3 ligands and re-activate dysfunctional T cells with co-stimulatory molecules in the tumor microenvironment. In a T-cell-inflamed phenotype, tumor eradication works best and is potentiated by immunotherapy such as checkpoint blockade. However, a majority of patients die despite receiving immunotherapy. One reason is insufficient T cell priming and infiltration in the tumor. Nature provides us with innate immune mechanisms in T-cell-inflamed tumors that we can adopt for more personalized immunotherapy strategies. Tumor sensing through innate signaling pathways and efficient antigen-presenting possess a significant role in bridging innate and adaptive immunity and generating a T-cell-inflamed tumor. One approach to strengthen these innate immune mechanisms is to deliver innate immune factors such as STING or activated DCs into the tumor microenvironment, in particular in patients resistant to checkpoint blockade. The low number of DCs in the tumor bed could potentially be increased with the growth factor FMS-like tyrosine kinase 3 ligand (Flt3L). CD103+ DCs are integral for three phases of anti-tumor immunity: priming, recruiting, and re-invigoration of effector T cells. Re-activation of dysfunctional T cells is achieved via co-stimulatory molecules such as the 4-1BB ligand. The presence of myeloid-cell-derived CXCL9 and CXCL10 in the tumor microenvironment can predict response to immunotherapy. We outline recent preclinical and clinical approaches to deliver these crucial components bridging innate and adaptive immunity into the tumor microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Interleukin-1 and Nuclear Factor Kappa B Signaling Promote Breast Cancer Progression and Treatment Resistance.
- Author
-
Diep, Sydney, Maddukuri, Mahita, Yamauchi, Stephanie, Geshow, Ganamee, and Delk, Nikki A.
- Subjects
NF-kappa B ,TUMOR necrosis factors ,AP-1 transcription factor ,INTERLEUKIN-1 receptors ,CANCER invasiveness ,CELL receptors - Abstract
While meant for wound healing and immunity in response to injury and infection, inflammatory signaling is usurped by cancerous tumors to promote disease progression, including treatment resistance. The interleukin-1 (IL-1) inflammatory cytokine family functions in wound healing and innate and adaptive immunity. Two major, closely related IL-1 family members, IL-1α and IL-1β, promote tumorigenic phenotypes and contribute to treatment resistance in cancer. IL-1 signaling converges on transactivation of the Nuclear Factor Kappa B (NF-κB) and Activator protein 1 (AP-1) transcription factors. NF-κB and AP-1 signaling are also activated by the inflammatory cytokine Tumor Necrosis Factor Alpha (TNFα) and microbe-sensing Toll-Like Receptors (TLRs). As reviewed elsewhere, IL-1, TNFα, and TLR can promote cancer progression through NF-κB or AP-1. In this review, we focus on what is known about the role of IL-1α and IL-1β in breast cancer (BCa) progression and therapeutic resistance, and state evidence for the role of NF-κB in mediating IL-1-induced BCa progression and therapeutic resistance. We will present evidence that IL-1 promotes BCa cell proliferation, BCa stem cell expansion, angiogenesis, and metastasis. IL-1 also regulates intracellular signaling and BCa cell hormone receptor expression in a manner that confers a growth advantage to the tumor cells and allows BCa cells to evade therapy. As such, the IL-1 receptor antagonist, anakinra, is in clinical trials to treat BCa and multiple other cancer types. This article presents a review of the literature from the 1990s to the present, outlining the evidence supporting a role for IL-1 and IL-1-NF-κB signaling in BCa progression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers.
- Author
-
Pao, Shih-Cheng, Chu, Mu-Tzu, and Hung, Shuen-Iu
- Subjects
T cells ,CANCER vaccines ,MAJOR histocompatibility complex ,IMMUNITY ,IMMUNE response ,CYTOTOXIC T cells ,NUCLEOTIDE sequencing - Abstract
Cancer immunotherapy has achieved multiple clinical benefits and has become an indispensable component of cancer treatment. Targeting tumor-specific antigens, also known as neoantigens, plays a crucial role in cancer immunotherapy. T cells of adaptive immunity that recognize neoantigens, but do not induce unwanted off-target effects, have demonstrated high efficacy and low side effects in cancer immunotherapy. Tumor neoantigens derived from accumulated genetic instability can be characterized using emerging technologies, such as high-throughput sequencing, bioinformatics, predictive algorithms, mass-spectrometry analyses, and immunogenicity validation. Neoepitopes with a higher affinity for major histocompatibility complexes can be identified and further applied to the field of cancer vaccines. Therapeutic vaccines composed of tumor lysates or cells and DNA, mRNA, or peptides of neoantigens have revoked adaptive immunity to kill cancer cells in clinical trials. Broad clinical applicability of these therapeutic cancer vaccines has emerged. In this review, we discuss recent progress in neoantigen identification and applications for cancer vaccines and the results of ongoing trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Dendrimers for cancer immunotherapy: Avidity‐based drug delivery vehicles for effective anti‐tumor immune response.
- Author
-
Rawding, Piper A., Bu, Jiyoon, Wang, Jianxin, Kim, Da Won, Drelich, Adam J., Kim, Youngsoo, and Hong, Seungpyo
- Abstract
Cancer immunotherapy, or the utilization of a patient's own immune system to treat cancer, has shifted the paradigm of cancer treatment. Despite meaningful responses being observed in multiple studies, currently available immunotherapy platforms have only proven effective to a small subset of patients. To address this, nanoparticles have been utilized as a novel carrier for immunotherapeutic drugs, achieving robust anti‐tumor effects with increased adaptive and durable responses. Specifically, dendrimer nanoparticles have attracted a great deal of scientific interest due to their versatility in various therapeutic applications, resulting from their unique physicochemical properties and chemically well‐defined architecture. This review offers a comprehensive overview of dendrimer‐based immunotherapy technologies, including their formulations, biological functionalities, and therapeutic applications. Common formulations include: (1) modulators of cytokine secretion of immune cells (adjuvants); (2) facilitators of the recognition of tumorous antigens (vaccines); (3) stimulators of immune effectors to selectively attack cells expressing specific antigens (antibodies); and (4) inhibitors of immune‐suppressive responses (immune checkpoint inhibitors). On‐going works and prospects of dendrimer‐based immunotherapies are also discussed. Overall, this review provides a critical overview on rapidly growing dendrimer‐based immunotherapy technologies and serves as a guideline for researchers and clinicians who are interested in this field. This article is categorized under:Nanotechnology Approaches to Biology > Nanoscale Systems in BiologyTherapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic DiseaseTherapeutic Approaches and Drug Discovery > Emerging Technologies [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Exosome application in tumorigenesis: diagnosis and treatment of melanoma.
- Author
-
Karami Fath, Mohsen, Azargoonjahromi, Ali, Jafari, Nafiseh, Mehdi, Maryam, Alavi, Fatemeh, Daraei, Mona, Mohammadkhani, Niloufar, Mueller, Anna-Lena, Brockmueller, Aranka, Shakibaei, Mehdi, and Payandeh, Zahra
- Abstract
Melanoma is the most aggressive of skin cancer derived from genetic mutations in the melanocytes. Current therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy, immunotherapy, biochemotherapy, and targeted therapy. However, the efficiency of these strategies may be decreased due to the development of diverse resistance mechanisms. Here, it has been proven that therapeutic monoclonal antibodies (mAbs) can improve the efficiency of melanoma therapies and also, cancer vaccines are another approach for the treatment of melanoma that has already improved clinical outcomes in these patients. The use of antibodies and gene vaccines provides a new perspective in melanoma treatment. Since the tumor microenvironment is another important factor for cancer progression and metastasis, in recent times, a mechanism has been identified to provide an opportunity for melanoma cells to communicate with remote cells. This mechanism is involved by a novel molecular structure, named extracellular vesicles (EVs). Depending on the functional status of origin cells, exosomes contain various cargos and different compositions. In this review, we presented recent progress of exosome applications in the treatment of melanoma. Different aspects of exosome therapy and ongoing efforts in this field will be discussed too. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. Know thy immune self and non‐self: Proteomics informs on the expanse of self and non‐self, and how and where they arise.
- Author
-
Joyce, Sebastian and Ternette, Nicola
- Published
- 2021
- Full Text
- View/download PDF
44. Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
- Author
-
Bai, Peng, Zhou, Qiuping, Wei, Pengcheng, Bai, Hua, Chan, Sanny K., Kappler, John W., Marrack, Philippa, and Yin, Lei
- Abstract
Cytotoxic T cells targeting cancer neoantigens harboring driver mutations can lead to durable tumor regression in an HLAI-dependent manner. However, it is difficult to extend the population of patients who are eligible for neoantigen-based immunotherapy, as immunogenic neoantigen-HLA pairs are rarely shared across different patients. Thus, a way to find other human leukocyte antigen (HLA) alleles that can also present a clinically effective neoantigen is needed. Recently, neoantigen-based immunotherapy targeting the KRAS G12D mutation in patients with HLA-C*08:02 has shown effectiveness. In a proof-of-concept study, we proposed a combinatorial strategy (the combination of phylogenetic and structural analyses) to find potential HLA alleles that could also present KRAS G12D neoantigen. Compared to in silico binding prediction, this strategy avoids the uneven accuracy across different HLA alleles. Our findings extend the population of patients who are potentially eligible for immunotherapy targeting the KRAS G12D mutation. Additionally, we provide an alternative way to predict neoantigen-HLA pairs, which maximizes the clinical usage of shared neoantigens. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. A Polysaccharide From the Whole Plant of Plantago asiatica L. Enhances the Antitumor Activity of Dendritic Cell-Based Immunotherapy Against Breast Cancer.
- Author
-
Gao, Jiafeng, Zhang, Yi-Nan, Cui, Jingwen, Zhang, Jiatong, Ming, Yuexiang, Hao, Zhihui, Xu, Huihao, Cheng, Nan, Zhang, Di, Jin, Yipeng, Lin, Degui, and Lin, Jiahao
- Subjects
T cells ,CYTOTOXIC T cells ,DENDRITIC cells ,PLANTAGO ,BREAST cancer ,BREAST tumors ,PLANT growth ,IMMUNOTHERAPY - Abstract
Dendritic cells (DCs) are the most potent professional antigen-presenting cells (APCs) that mediate T-cell immune responses. Breast cancer is one of the most commonly diagnosed diseases and its mortality rate is higher than any other cancer in both humans and canines. Plantain polysaccharide (PLP), extracted from the whole plant of Plantago asiatica L., could promote the maturation of DCs. In this research, we found that PLP could upregulate the maturation of DCs both in vitro and in vivo. PLP-activated DCs could stimulate lymphocytes' proliferation and differentiate naive T cells into cytotoxic T cells. Tumor antigen-specific lymphocyte responses were enhanced by PLP and CIPp canine breast tumor cells lysate-pulsed DCs, and PLP and CIPp-cell-lysate jointly stimulated DCs cocultured with lymphocytes having the great cytotoxicity on CIPp cells. In the 4T1 murine breast tumor model, PLP could control the size of breast tumors and improve immunity by recruiting DCs, macrophages, and CD4
+ and CD8+ T cells in the tumor microenvironment. These results indicated that PLP could achieve immunotherapeutic effects and improve immunity in the breast tumor model. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
46. Osteoking Decelerates Cartilage Degeneration in DMM-Induced Osteoarthritic Mice Model Through TGF-β/smad-dependent Manner.
- Author
-
Ling, Houfu, Zeng, Qinghe, Ge, Qinwen, Chen, Jiali, Yuan, Wenhua, Xu, Rui, Shi, Zhenyu, Xia, Hanting, Hu, Songfeng, Jin, Hongting, Wang, Pinger, and Tong, Peijian
- Subjects
LABORATORY mice ,ANIMAL disease models ,CARTILAGE ,CHINESE medicine ,CARTILAGE cells ,TRANSGENIC mice ,MATRIX metalloproteinases - Abstract
Osteoarthritis (OA) is a common disease characterized by cartilage degeneration. In recent years much attention has been paid to Traditional Chinese Medicine (TCM) since its treatments have shown efficacy for ameliorating cartilage degradation with mild side effects. Osteoking is a TCM prescription that has long been used in OA treatment. However, the exact mechanism of Osteoking are not fully elucidated. In the current study, destabilization of the medial meniscus (DMM)-induced OA mice was introduced as a wild type animal model. After 8 weeks of administration of Osteoking, histomorphometry, OARSI scoring, gait analysis, micro-CT, and immunohistochemical staining for Col2, MMP-13, TGFβRII and pSmad-2 were conducted to evaluate the chondroprotective effects of Osteoking in vivo. Further in vitro experiments were then performed to detect the effect of Osteoking on chondrocytes. TGFβRII
Col2ER transgenic mice were constructed and introduced in the current study to validate whether Osteoking exerts its anti-OA effects via the TGF-β signaling pathway. Results demonstrated that in wild type DMM mice, Osteoking ameliorated OA-phenotype including cartilage degradation, subchondral bone sclerosis, and gait abnormality. Col2, TGFβRII, and pSmad-2 expressions were also found to be up-regulated after Osteoking treatment, while MMP-13 was down-regulated. In vitro , the mRNA expression of MMP-13 and ADAMTS5 decreased and the mRNA expression of Aggrecan, COL2, and TGFβRII were up-regulated after the treatment of Osteoking in IL-1β treated chondrocytes. The additional treatment of SB505124 counteracted the positive impact of Osteoking on primary chondrocytes. In TGFβRIICol2ER mice, spontaneous OA-liked phenotype was observed and treatment of Osteoking failed to reverse the OA spontaneous progression. In conclusion, Osteoking ameliorates OA progression by decelerating cartilage degradation and alleviating subchondral bone sclerosis partly via the TGF-β signaling pathway. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
47. The immunoregulatory role of p21 in the development of the temporomandibular joint‐osteoarthritis.
- Author
-
Khurel‐Ochir, Tsendsuren, Izawa, Takashi, Iwasa, Akihiko, Kano, Fumiya, Yamamoto, Akihito, and Tanaka, Eiji
- Subjects
IMMUNOMODULATORS ,TEMPOROMANDIBULAR joint ,OSTEOARTHRITIS - Abstract
Objective: We aimed to identify the immunoregulatory role of the cyclin‐dependent kinase inhibitor p21 in the homeostasis of mandibular condylar cartilage affected by mechanical stress. Materials and methods: Ten C57BL/6 wild‐type (WT) and ten p21−/− mice aged 8 weeks were divided into the untreated and treated groups. In the treated groups, mechanical stress was applied to the temporomandibular joint (TMJ) through forced mouth opening for 3 hr/day for 7 days. The dissected TMJs were assessed using micro‐CT, histology, and immunohistochemistry. Results: Treated p21−/− condyles with mechanical stress revealed more severe subchondral bone destruction, with thinner cartilage layers and smaller proteoglycan area relative to treated WT condyles; untreated WT and p21−/− condyles had smoother surfaces. Immunohistochemistry revealed significant increases in the numbers of caspase‐3, interleukin‐1β, matrix metalloprotease (MMP)‐9, and MMP‐13 positive cells, and few aggrecan positive cells, in treated p21−/− than in treated WT samples. Moreover, the number of TUNEL positive cells markedly increased in p21−/− condyles affected by mechanical stress. Conclusions: Our findings indicate that p21 in chondrocytes contributes to regulate matrix synthesis via the control ofm aggrecan and MMP‐13 expression under mechanical stress. Thus, p21 might regulate the pathogenesis of osteoarthritis in the TMJ. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. MarketLine Company Profile: W. R. Berkley Corp.
- Published
- 2020
49. Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells in vitro.
- Author
-
Radojević, Dušan, Tomić, Sergej, Mihajlović, Dušan, Tolinački, Maja, Pavlović, Bojan, Vučević, Dragana, Bojić, Svetlana, Golić, Nataša, Čolić, Miodrag, and Đokić, Jelena
- Published
- 2021
- Full Text
- View/download PDF
50. Novel high‐docosahexaenoic‐acid tuna oil supplementation modulates gut microbiota and alleviates obesity in high‐fat diet mice.
- Author
-
Zhang, Jing, Yi, Congmin, Han, Jiaojiao, Ming, Tinghong, Zhou, Jun, Lu, Chenyang, Li, Ye, and Su, Xiurong
- Subjects
DOCOSAHEXAENOIC acid ,OMEGA-3 fatty acids ,GUT microbiome ,FISH oils ,EICOSAPENTAENOIC acid ,HIGH-fat diet ,PROLINE metabolism - Abstract
Studies have documented the benefits of fish oil in different diseases because of its high n‐3 polyunsaturated fatty acid content. However, these studies mostly used commercially available fish oil supplements with a ratio of 18/12 for eicosapentaenoic acid and docosahexaenoic acid (DHA). However, increasing DHA content for this commonly used ratio might bring out a varied metabolic effect, which have remained unclear. Thus, in this study, a novel tuna oil (TO) was applied to investigate the effect of high‐DHA content on the alteration of the gut microbiota and obesity in high‐fat diet mice. The results suggest that high‐DHA TO (HDTO) supplementation notably ameliorates obesity and related lipid parameters and restores the expression of lipid metabolism‐related genes. The benefits of TOs were derived from their modification of the gut microbiota composition and structure in mice. A high‐fat diet triggered an increased Firmicutes/Bacteroidetes ratio that was remarkably restored by TOs. The number of obesity‐promoting bacteria—Desulfovibrio, Paraeggerthella, Terrisporobacter, Millionella, Lachnoclostridium, Anaerobacterium, and Ruminiclostridium—was dramatically reduced. Desulfovibrio desulfuricans, Alistipes putredinis, and Millionella massiliensis, three dysbiosis‐related species, were especially regulated by HDTO. Regarding the prevention of obesity, HDTO outperforms the normal TO. Intriguingly, HDTO feeding to HFD‐fed mice might alter the arginine and proline metabolism of intestinal microbiota. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.